MediciNova (MNOV) Q2 2026 earnings summary

Executive summary

• Focused on developing MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic/metabolic diseases, with a commercial focus on the U.S. market.

• Accumulated deficit reached $443.6 million as of June 30, 2026, with expectations of continued net losses as development progresses.

• Revenue growth in 2026 driven by clinical research services for Mayo Foundation ALS study.

Financial highlights

• Revenues for Q2 2026 were $0.5 million, up from $0.1 million in Q2 2025, due to increased services for Mayo.

• Net loss for Q2 2026 was $2.3 million, an improvement from $3.3 million in Q2 2025.

• Six-month net loss was $4.9 million, improved from $6.1 million year-over-year.

• Cash and cash equivalents totaled $25.4 million as of June 30, 2026.

• Working capital stood at $23.0 million, sufficient to fund operations through at least November 2027.

Outlook and guidance

• Expects to incur substantial net losses for several years as clinical programs advance.

• Believes current cash resources are sufficient for at least the next 12 months.

• Plans to pursue additional strategic alliances and non-dilutive financing to support development.